Sagimet Biosciences Inc. (SGMT) Scorecard
- 2026-Q2: Total return Win; Revenue growth No data; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth No data; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth No data; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth No data; EPS growth Win.
5/21
1.2 / 5 stars
All 21 Win/Lose results and 99 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 2 wins, 6 losses, 4 no dataLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/2 |
WinSGMT / S&P 47.94% / 15.20% |
No dataSGMT / S&P / 15.00% |
LoseSGMT / S&P -29.51% / 50.40% |
| 2026-Q10/2 |
LoseSGMT / S&P -11.74% / -4.33% |
No dataSGMT / S&P / 11.30% |
LoseSGMT / S&P -23.30% / 27.70% |
| 2025-Q40/2 |
LoseSGMT / S&P -13.70% / 2.65% |
No dataSGMT / S&P / 9.00% |
LoseSGMT / S&P 10.49% / 13.40% |
| 2025-Q31/2 |
LoseSGMT / S&P -9.97% / 8.12% |
No dataSGMT / S&P / 4.61% |
WinSGMT / S&P 381.08% / 13.45% |
| 2025-Q22/2 |
WinSGMT / S&P 133.74% / 10.94% |
No dataSGMT / S&P / 4.83% |
WinSGMT / S&P 577.78% / 10.63% |
| 2025-Q10/2 |
LoseSGMT / S&P -27.56% / -4.27% |
No dataSGMT / S&P / 4.98% |
LoseSGMT / S&P -95.09% / 10.57% |
| 2024-Q41/2 |
WinSGMT / S&P 62.45% / 2.41% |
No dataSGMT / S&P / 5.25% |
LoseSGMT / S&P -97.99% / 6.15% |
| 2024-Q30/2 |
LoseSGMT / S&P -19.01% / 5.89% |
No dataSGMT / S&P / 5.89% |
LoseSGMT / S&P -99.67% / 6.11% |
| 2024-Q20/2 |
LoseSGMT / S&P -36.90% / 4.28% |
No dataSGMT / S&P / 5.38% |
LoseSGMT / S&P -99.82% / 5.12% |
| 2024-Q10/2 |
LoseSGMT / S&P 0.00% / 10.56% |
No dataSGMT / S&P / 5.71% |
LoseSGMT / S&P -76.64% / 5.59% |
| 2023-Q40/1 |
LoseSGMT / S&P -38.41% / 11.69% |
No dataSGMT / S&P / 6.81% |
No dataSGMT / S&P / 7.78% |
| 2023-Q30/0 |
No dataSGMT / S&P / -3.27% |
No dataSGMT / S&P / 7.52% |
No dataSGMT / S&P / -5.03% |
| 2023-Q20/0 |
No dataSGMT / S&P / 8.74% |
No dataSGMT / S&P / 9.50% |
No dataSGMT / S&P / -8.57% |
| 2023-Q10/0 |
No dataSGMT / S&P / 7.50% |
No dataSGMT / S&P / 10.77% |
No dataSGMT / S&P / -15.69% |
| 2022-Q40/0 |
No dataSGMT / S&P / 7.56% |
No dataSGMT / S&P / 11.88% |
No dataSGMT / S&P / -17.99% |
| 2022-Q30/0 |
No dataSGMT / S&P / -4.88% |
No dataSGMT / S&P / 13.47% |
No dataSGMT / S&P / -1.41% |
| 2022-Q20/0 |
No dataSGMT / S&P / -16.10% |
No dataSGMT / S&P / 13.71% |
No dataSGMT / S&P / 11.04% |
| 2022-Q10/0 |
No dataSGMT / S&P / -4.60% |
No dataSGMT / S&P / 15.97% |
No dataSGMT / S&P / 42.23% |
| 2021-Q40/0 |
No dataSGMT / S&P / 11.03% |
No dataSGMT / S&P / 15.00% |
No dataSGMT / S&P / 96.40% |
| 2021-Q30/0 |
No dataSGMT / S&P / 0.58% |
No dataSGMT / S&P / 10.77% |
No dataSGMT / S&P / 69.42% |
| 2021-Q20/0 |
No dataSGMT / S&P / 8.55% |
No dataSGMT / S&P / 6.58% |
No dataSGMT / S&P / 51.81% |
| 2021-Q10/0 |
No dataSGMT / S&P / 6.17% |
No dataSGMT / S&P / -1.06% |
No dataSGMT / S&P / 7.39% |
| 2020-Q40/0 |
No dataSGMT / S&P / 12.15% |
No dataSGMT / S&P / -3.72% |
No dataSGMT / S&P / -33.42% |
| 2020-Q30/0 |
No dataSGMT / S&P / 8.93% |
No dataSGMT / S&P / -2.04% |
No dataSGMT / S&P / -27.10% |
| 2020-Q20/0 |
No dataSGMT / S&P / 20.54% |
No dataSGMT / S&P / -0.46% |
No dataSGMT / S&P / -27.11% |
| 2020-Q10/0 |
No dataSGMT / S&P / -19.60% |
No dataSGMT / S&P / 3.47% |
No dataSGMT / S&P / -14.75% |
| 2019-Q40/0 |
No dataSGMT / S&P / 9.07% |
No dataSGMT / S&P / 5.36% |
No dataSGMT / S&P / 2.99% |
| 2019-Q30/0 |
No dataSGMT / S&P / 1.70% |
No dataSGMT / S&P / 5.02% |
No dataSGMT / S&P / 0.21% |
| 2019-Q20/0 |
No dataSGMT / S&P / 4.30% |
No dataSGMT / S&P / 6.64% |
No dataSGMT / S&P / 8.65% |
| 2019-Q10/0 |
No dataSGMT / S&P / 13.65% |
No dataSGMT / S&P / 8.12% |
No dataSGMT / S&P / 14.29% |
| 2018-Q40/0 |
No dataSGMT / S&P / -13.52% |
No dataSGMT / S&P / 9.05% |
No dataSGMT / S&P / 18.23% |
| 2018-Q30/0 |
No dataSGMT / S&P / 7.71% |
No dataSGMT / S&P / 10.21% |
No dataSGMT / S&P / 19.06% |
| 2018-Q20/0 |
No dataSGMT / S&P / 3.43% |
No dataSGMT / S&P / 9.03% |
No dataSGMT / S&P / 14.46% |
| 2018-Q10/0 |
No dataSGMT / S&P / -0.76% |
No dataSGMT / S&P / 7.68% |
No dataSGMT / S&P / 12.46% |
| 2017-Q40/0 |
No dataSGMT / S&P / 6.64% |
No dataSGMT / S&P / 7.03% |
No dataSGMT / S&P / 13.82% |
| 2017-Q30/0 |
No dataSGMT / S&P / 4.48% |
No dataSGMT / S&P / 5.68% |
No dataSGMT / S&P / 17.57% |
| 2017-Q20/0 |
No dataSGMT / S&P / 3.09% |
No dataSGMT / S&P / 4.83% |
No dataSGMT / S&P / 17.74% |
| 2017-Q10/0 |
No dataSGMT / S&P / 6.07% |
No dataSGMT / S&P / 3.67% |
No dataSGMT / S&P / 13.32% |
| 2016-Q40/0 |
No dataSGMT / S&P / 3.82% |
No dataSGMT / S&P / 2.09% |
No dataSGMT / S&P / 7.05% |
| 2016-Q30/0 |
No dataSGMT / S&P / 3.85% |
No dataSGMT / S&P / 0.20% |
No dataSGMT / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | SGMT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 43.14% | 20.78% |
| Annualized return | 43.14% | 20.78% |
5Y · 2023-07-14 to 2026-08-27
| Metric | SGMT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -32.60% | 83.14% |
| Annualized return | -7.59% | 12.86% |
10Y · 2023-07-14 to 2026-08-27
| Metric | SGMT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -32.60% | 319.30% |
| Annualized return | -3.87% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |